淋巴瘤的双特异性抗体治疗

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 DOI:10.1016/j.beha.2025.101598

Genevieve M. Gerhard, Gottfried von Keudell

{"title":"淋巴瘤的双特异性抗体治疗","authors":"Genevieve M. Gerhard, Gottfried von Keudell","doi":"10.1016/j.beha.2025.101598","DOIUrl":null,"url":null,"abstract":"<div><div>The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL. With the number of anti-lymphoma drugs increasing every year, it is important to optimize clinical trial analysis and design so that outcomes, toxicities, and predictors thereof can be understood and compared amongst therapeutic classes to ensure that patients get the safest and most effective treatments for them at the most appropriate line of therapy.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 4","pages":"Article 101598"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bispecific antibody therapy for lymphoma\",\"authors\":\"Genevieve M. Gerhard, Gottfried von Keudell\",\"doi\":\"10.1016/j.beha.2025.101598\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL. With the number of anti-lymphoma drugs increasing every year, it is important to optimize clinical trial analysis and design so that outcomes, toxicities, and predictors thereof can be understood and compared amongst therapeutic classes to ensure that patients get the safest and most effective treatments for them at the most appropriate line of therapy.</div></div>\",\"PeriodicalId\":8744,\"journal\":{\"name\":\"Best Practice & Research Clinical Haematology\",\"volume\":\"37 4\",\"pages\":\"Article 101598\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best Practice & Research Clinical Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521692625000039\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Haematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521692625000039","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在过去的十年中，b细胞非霍奇金淋巴瘤（B-NHL）新疗法的快速发展为该领域提供了一个关键的拐点。双特异性抗体是一种治疗B-NHL的有效、现成的选择。在这篇综述中，我们主要关注弥漫性大b细胞淋巴瘤（DLBCL），重点介绍了目前已批准或正在临床试验的B-NHL双特异性抗体的演变、比较、耐受性、持续挑战和未来潜力。随着抗淋巴瘤药物的数量逐年增加，优化临床试验分析和设计是非常重要的，以便了解和比较不同治疗类别的结果、毒性和预测因素，以确保患者在最合适的治疗路线上获得最安全、最有效的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bispecific antibody therapy for lymphoma

The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL. With the number of anti-lymphoma drugs increasing every year, it is important to optimize clinical trial analysis and design so that outcomes, toxicities, and predictors thereof can be understood and compared amongst therapeutic classes to ensure that patients get the safest and most effective treatments for them at the most appropriate line of therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.